Recruiting
Neoplasm
RecruitingRegistered drugNo placebo
Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors
Registered drugNo placebo
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Adagrasib
Find therapies in clinical trials near you – page 4
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
767 trials match your criteria
Recruiting
Dermatitis atopic
RecruitingRegistered drug
Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis
Registered drug
- Disease:Dermatitis atopic
- Substances:Sodium Chloride
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Sodium Chloride
Recruiting
Renal transplant
RecruitingRegistered drug
Safety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression
Registered drug
- Disease:Renal transplant
- Substances:SiplizumabRabbit Anti-Human Thymocyte Immunoglobulin
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Siplizumab
Recruiting
Malignant melanoma stage III
RecruitingRegistered drugNo placebo
A Randomized Double‑Blind Study of Pharmacokinetic Similarity of AVT32‑DRL_PB and Pembrolizumab in Patients with Resected Stage IIB‑C‑III Melanoma
Registered drugNo placebo
- Disease:Malignant melanoma stage III
- Substances:Pembrolizumab
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
Recruiting
Polycythaemia vera
RecruitingInvestigational
A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera
Investigational
- Disease:Polycythaemia vera
- Substances:Sapablursen
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Sapablursen
Recruiting
HIV infection
RecruitingRegistered drugNo placebo
Cabotegravir and Rilpivirine Ultra‑Long‑Acting vs Long‑Acting in Adults and Adolescents with HIV Who Are Virally Suppressed
Registered drugNo placebo
- Disease:HIV infection
- Substances:CabotegravirRilpivirine
Countries:Spain
Spain- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Cabotegravir
Recruiting
Systemic scleroderma
RecruitingInvestigational
A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis
Investigational
- Disease:Systemic scleroderma
- Substances:Bi 10155501-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Bi 1015550
Recruiting
Small cell lung cancer
RecruitingRegistered drugNo placebo
Safety and Tolerability of Alisertib Sodium and Paclitaxel in Patients with Small Cell Lung Cancer (Phase 2 Study)
Registered drugNo placebo
- Disease:Small cell lung cancer
- Substances:Alisertib SodiumPaclitaxel
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Alisertib Sodium
Recruiting
Obesity
RecruitingInvestigational
Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes
Investigational
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Azd5004
Recruiting
Oesophageal adenocarcinoma
RecruitingRegistered drugNo placebo
Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma
Registered drugNo placebo
- Disease:Oesophageal adenocarcinoma
- Substances:Calcium FolinateDocetaxel+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Calcium Folinate
Recruiting
HIV infection
RecruitingRegistered drugNo placebo
Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study
Registered drugNo placebo
- Disease:HIV infection
- Substances:AbacavirAtazanavir+16
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Abacavir
Recruiting
Asthma
RecruitingRegistered drug
Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations
Registered drug
- Disease:Asthma
- Substances:Depemokimab
Countries:Spain
Spain- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Depemokimab